EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Prospects and Challenges of Genetically Modified Live-Attenuated Leishmania Vaccines

Suman Karmakar, Mousumi Das, Monalisa Ray, Soumyadip Mukherjee, Sanhita Ghosh, Kamalika Roy, Chiranjib Pal

Zoonoses · 2024 · 4 (1)

DOI: 10.15212/zoonoses-2024-0010 ↗
AbstractBibliografische Angaben

Abstract

Leishmaniases are transmitted by the protozoan parasite Leishmania through the bites of infected sandflies. Despite the availability of various medications, rising resistance and toxicity levels underscore the urgent need to explore and create a reliable, safe vaccine for human use. Creating live attenuated promastigotes by genetically modifying essential gene targets affects their virulence without influencing their immunogenic attribution, and has shown highly promising reproducibility. These vaccines provide protection against challenge with virulent wild-type parasites. Advances in CRISPR/Cas9 gene editing technology have shown promise in enabling marker-free gene modification. Herein, our aim is to shed light on genetically modified Leishmania with the potential to confer protection against wild-type Leishmania challenge in animal models. Because of several limitations, the success has not been achieved to date. Therefore, additional potential candidates with high effectiveness must be assessed as potential vaccines in the future.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →